Cytomegalovirus triggering autoimmune hepatitis: case report and literature review

Neil Vyas1, Rafael Ching Companioni2, James Nguyen1, Hassan Alkhawam1, Robert Sogomonian1, Ishan Patel1, Joel Baum2, Aaron Walfish2

1Department of Internal Medicine, Elmhurst Hospital Center, Elmhurst NY, USA.
2Department of Gastroenterology, Elmhurst Hospital Center, Elmhurst NY, USA.
Correspondence to: Neil Vyas, E-mail: Neil.vyas@mssm.edu
Received May 22, 2016. Accepted August 5, 2016

Abstract

Cytomegalovirus (CMV) is considered to play a role in triggering autoimmune hepatitis (AIH). It is difficult to diagnose autoimmune hepatitis because its presentation can be acute, severe, asymptomatic or chronic. Diagnosis requires multiple findings and exclusions of similar diseases. When excluding, viral etiologies are part of the differential, which in this case is CMV. If a trigger is required to set off a sequence of events leading to autoimmune hepatitis in these predisposed individuals, viruses are among the most likely candidates. In this study, a case of a 54 year-old female who presents with new onset of jaundice, associated with abdominal distension, lower extremity edema and 10 pound weight gain is reported. The autoimmune workup of the patient was significant for an elevated antibodies to nuclei (ANA) titer, anti-smooth muscle ab titer and a significant increase in immunoglobulins, specifically IgG. Interestingly, CMV Ab IgM was positive as well as CMV Ab IgG. A liver biopsy was performed which showed heavy infiltration with lymphoplasmacytic inflammatory cells, interface hepatitis, bridging necrosis and fibrosis. These pathologic and laboratory findings led us to a definitive diagnosis of AIH Type 1. In the setting of positive CMV IgG and IgM ab titers, we suggest that the trigger for AIH in this case was a preceding CMV infection. Patient improved with combination of azathioprine and corticosteroid therapy despite intermittent flares of the patient’s AIH.

KEYWORDS: Autoimmune hepatitis (AIH), cytomegalovirus (CMV), liver disease

Introduction

Autoimmune hepatitis (AIH) is a chronic inflammatory condition of the liver with unknown etiology. It has a population prevalence of 0.01–0.02% and typically occurs in females.[1] AIH causes chronic hepatocellular inflammation and necrosis within the liver lobules. This is a response to the body’s own immune system attacking liver surface membrane antigens[1] leading to cirrhosis and possibly liver failure.[1,2,4] AIH is divided into two types: Type 1 AIH is characterized by circulating antibodies to nuclei (ANA) or smooth muscle (ASMA) and

Type 2 AIH is characterized by the presence of antibodies to liver or kidney microsomes (ALKM-1) and/or to a liver cytosol antigen (ALC-1).[1,3,4] ALKM-1 serve as a serologic marker for AIH type 2, and it reacts with recombinant antigen cytochrome monoxygenase P450. Type 1 is typically characterized as 70% female with peak incidence between ages 16 and 30 years old. Type 2 is rare overall and 20 times less frequent than type 1.[1] At the time of diagnosis, there was 25% of cirrhosis, characterized by high titer (>1:80), ANA (homogenous or speckled pattern) reactive with chromatin and occasionally dsDNA and ASMA, reactive with F-actin microfilaments. Histologically, the liver biopsy reveals a chronic necroinflammatory disorder characterized by nonspecific findings such as portal mononuclear cell infiltrate, periportal lesion (sometimes referred to as piecemeal necrosis or interface hepatitis), bile duct changes, destructive, and non destructive cholangitis and ductopenia present in 25% of patients, plasma cell infiltrate and liver fibrosis.[7] The causes of AIH are still unclear, however viruses are suggested in playing a role in predisposed individuals. In this study, a unique case of CMV triggering autoimmune hepatitis is presented.
Case Report

Patient is a 54 year-old female who presents with new onset of jaundice, associated with abdominal distension, lower extremity edema and 10 pound weight gain. The patient has no history of intravenous drug use, blood transfusions, any new sexual partners in over 8 years or a family history of liver disease. The physical examination was remarkable for spider angiomata, icteric sclera, ascites, and bilateral lower extremity edema.

The results of the biochemical analysis of the blood were the following: liver enzymes were all elevated, ALP 162 U/L, GGT 65 U/L, AST 154 U/L, ALT 72 U/L. The patient’s autoimmune workup was significant for an elevated ANA titer of 1:640, anti-smooth muscle ab titer 1:40, and a significant increase in immunoglobulins (Ig), specifically IgG which was 4100 mg/dL. Interestingly, CMV Ab IgM was positive at 36.6 u/mL as well as CMV Ab IgG, which was positive at >10.00 u/mL. The rest of the work up including hepatitis A, B, C, HIV, HSV, Epstein Barr virus (EBV), alpha1 antitrypsin, ceruloplasmin, iron level, ferritin, and antimitochondrial ab (was unremarkable). A liver biopsy was performed which showed heavy infiltration with lymphoplasmacytic inflammatory cells, interface hepatitis, bridging necrosis, and fibrosis (see Figure 1 and 2). These pathologic and laboratory findings led to a definitive diagnosis of autoimmune hepatitis (AIH) Type 1. In the setting of positive CMV IgG and IgM ab titers, we suggest that the trigger for AIH in this case was a preceding CMV infection.

Patient improved with the following treatment with combination of azathioprine and corticosteroid therapy. Patient improved with combination of azathioprine and corticosteroid therapy despite intermittent flares of AIH. The patient has tapered off steroids in a period of 2 months but continues to use azathioprine. Patients liver enzymes and total billirubin have downtrended while immunoglobulins have worsened. However, clinically improved ascites and jaundice.

Discussion

Viruses are suggested to play a role in triggering autoimmune hepatitis. AIH due to viral pathogenesis have been debated and several proposed theories have emerged. One proposed theory that has been gaining support which is considered the main viral pathogenesis is molecular mimicry. The theory suggests that environmental triggers such as viruses along with failure of immune tolerance and a genetic predisposition, induces T-cell mediated immune attacks against the liver antigens leading to a progressive necroinflammatory and fibrotic process in the liver.[4]

The relationship is between the genetics of the individual and the autoimmune process at the molecular level. This specific process involves antigen, the major histocompatibility complex (MHC), and T cell receptor (TCR). Moreover, there is research suggesting cross-reactivity between ALKM-1 against homologous regions of cytomegalovirus (exon CMV130-135). Since the CMV IgM and IgG ab titers were positive in this patient. LKM1 antibody may arise from recognizing the exon 130-135 on the cytomegalovirus, which is seen in 4% of the cases. However, this antibody also recognizes the major epitope of CYP2D6 of P450 system (amino acids 254-271), causing this cross-reactivity.[1, 5] Manns et al.[5] suggested that reactivity to the major epitope LKM1 is also seen in response to amino acids 310–324 of the envelope region E1 of hepatitis C (HCV) and amino acids 156–170 of the immediate early protein E1 and the herpes simplex virus type 1 (HSV1). LKM1 antibodies are found in up to 10% of patients with hepatitis C virus infection and appear to correlate with increased disease severity and adverse reactions to interferon.[4, 5] Given the patient was HCV and HSV negative, these are not viable options.

Treatment is generally aimed at decreasing the inflammatory process. A scoring system has been implemented to determine the prognosis of AIH. In 1993 a scoring system was done by the international panel and revised in 1999. According to
the revised original scoring system of the international autoimmune hepatitis group pretreatment score of 15 points or higher is indicative of definitive AIH with a sensitivity of 95% and specificity of 97%,[5] in our specific case the calculated score of the patient was 41. More recently, a simplified scoring system has been developed based on presence and level of autoantibody expression by indirect immunofluorescence, serum IgG concentration, compatible or typical histological features and the absence of viral markers. Moreover, 40% of patients with untreated severe disease died within 6 months of diagnosis and survivors frequently developed cirrhosis, esophageal varices and subsequent hemorrhage. Three randomized, control trials have demonstrated that patients with serum AST levels 10 times upper limit normal (ULN) or more than 5 times ULN with serum y-globulin level more than two-fold ULN, have a high mortality (60% at 6 months) if untreated.[6] This patient did not meet this criteria; however, did have a liver biopsy which showed heavy infiltration with lymphoplasmacytic inflammatory cells (image 2), interface hepatitis (image 1), bridging necrosis and fibrosis, which is associated with a 5-year mortality of 45% and an absolute indication for corticosteroid treatment. Randomized controlled treatment trials established that prednisone alone or in combination with azathioprine improved symptoms, laboratory tests, histological findings, and immediate survival. These studies led to the acceptance of immunosuppressive regimens as the standard in treatment.[7]

AIH has a heterogeneous and fluctuating nature, leading to marked variability in its clinical manifestations. Its spectrum ranges from asymptomatic patients to those with considerable and sometimes debilitating symptoms, and even those with acute liver failure. What is poorly understood is the pathogenesis. Predisposed individuals are directed toward genes encoding human leukocyte antigens (HLA). Classical (type 1) autoimmune hepatitis (AIH) is strongly associated with the HLA haplotype A1, B8, DR3 and with DR3 and DR4 allotypes.[8] HLA-DR3 associated disease is more commonly found in the early onset severe form of disease (while, HLA D4 is more common in Caucasians with late onset of disease and is associated with higher incidence of extra hepatic manifestations with a better response to corticosteroids.[9-11]. We must include viral etiology in the differential for patients who have AIH because there is a combination of genetic and environmental exposures including infectious agents such as CMV. Cross reactive theories such as molecular mimicry, has been gaining strong experimental support. However, research on exact mechanisms can help guide clinical strategies for prevention and even allow therapy.

In regards to the present case, immunologically the patient had a positive ANA, positive anti-smooth muscle Ab, hyper gammaglobulinemia and had an AIH international score of 41. Histologically, the biopsy showed characteristic AIH findings such as confluent necrosis with collapsed areas heavily infiltrated by lymphoplasmacytic inflammatory cells. Plasma cells occur in groups and severe interface hepatitis noted. The remaining lobules show numerous foci of necroinflammation and cholestasis. Trichrome stain shows portal fibrosis with fibrous septa that bridge and partially enclose nodules. With the above mentioned findings plus positive CMV IgG and IgM ab titers, led to a final diagnosis of AIH Type 1 and reveals a possible link between viruses more specifically CMV and autoimmune hepatitis. More clinical observations and evidence are needed to define a possible role for viruses such as CMV in the pathogenesis of AIH.[1, 3]

**Conclusion**

CMV is considered to play a role in triggering AIH. It is difficult to diagnose AIH because its presentation can be acute, severe, asymptomatic or chronic. Diagnosis requires multiple findings and exclusions of similar diseases. When excluding, make sure viral etiologies are part of the differential, which in this case is CMV. If a trigger is required to set off a sequence of events leading to AIH in these predisposed individuals, viruses are among the most likely candidates.

**References**


**Source of Support:** Nil, **Conflict of Interest:** None declared.